share_log

FDA Approves KEYTRUDA As Adjuvant Treatment Following Surgical Resection And Platinum-Based Chemotherapy For Patients With Stage IB (T2a ≥4 Centimeters), II, Or IIIA Non-Small Cell Lung Cancer (NSCLC)

Benzinga Real-time News ·  Jan 27, 2023 06:53
FDA Approves KEYTRUDA As Adjuvant Treatment Following Surgical Resection And Platinum-Based Chemotherapy For Patients With Stage IB (T2a ≥4 Centimeters), II, Or IIIA Non-Small Cell Lung Cancer (NSCLC)
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment